Medical resource utilization and the associated costs of asthma in China: a 1-year retrospective study

[1] Huang K(2019)Prevalence, risk factors, and management of asthma in China: a national cross-sectional study Lancet 394 407-18

[2] Yang T(2020)[Meta-analysis of asthma prevalence of children aged 0–14 in surveillance cities of China] Zhonghua Yu Fang Yi Xue Za Zhi 54 875-83

[3] Xu J(2018)Prevalence and risk factors of asthma in mainland China: the CARE study Respir Med 137 48-54

[4] Yang L(2022)Direct Medical cost of Pediatric Asthma in Jordan: a cost-of-illness Retrospective Cohort Study Value Health Reg Issues 31 10-7

[5] Zhao J(2022)Economic burden of severe asthma treatment: a real-life study World Allergy Organ J 15 100662-39

[6] Zhang X(2020)Pharmacoeconomic management of patient with severe asthma in the Emergency Department: retrospective multicentric and cost of illness study Eur Rev Med Pharmacol Sci 24 11729-9

[7] Shu W(2022)Asthma burden according to treatment steps in the french population-based cohort CONSTANCES Respir Med 49 303-83

[8] Li ML(2012)Economic costs for adult asthmatics according to severity and control status in korean tertiary hospitals J Asthma 23 723-40

[9] Li ZA(2004)Asthma severity and medical resource utilisation Eur Respir J 6 75-43

[10] Hu Y-f(2003)Costs of asthma in a cohort of swiss adults: associations with exacerbation status and severity Value Health 38 437-4

[1] Huang K(2019)Prevalence, risk factors, and management of asthma in China: a national cross-sectional study Lancet 394 407-18

[2] Yang T(2020)[Meta-analysis of asthma prevalence of children aged 0–14 in surveillance cities of China] Zhonghua Yu Fang Yi Xue Za Zhi 54 875-83

[3] Xu J(2018)Prevalence and risk factors of asthma in mainland China: the CARE study Respir Med 137 48-54

[4] Yang L(2022)Direct Medical cost of Pediatric Asthma in Jordan: a cost-of-illness Retrospective Cohort Study Value Health Reg Issues 31 10-7

[5] Zhao J(2022)Economic burden of severe asthma treatment: a real-life study World Allergy Organ J 15 100662-39

[6] Zhang X(2020)Pharmacoeconomic management of patient with severe asthma in the Emergency Department: retrospective multicentric and cost of illness study Eur Rev Med Pharmacol Sci 24 11729-9

[7] Shu W(2022)Asthma burden according to treatment steps in the french population-based cohort CONSTANCES Respir Med 49 303-83

[8] Li ML(2012)Economic costs for adult asthmatics according to severity and control status in korean tertiary hospitals J Asthma 23 723-40

[9] Li ZA(2004)Asthma severity and medical resource utilisation Eur Respir J 6 75-43

[10] Hu Y-f(2003)Costs of asthma in a cohort of swiss adults: associations with exacerbation status and severity Value Health 38 437-4